Aridis Pharmaceuticals, Inc.

45 articles with Aridis Pharmaceuticals, Inc.

• Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer

  10/11/2019

  Aridis Pharmaceuticals, Inc. announced that it has appointed Paul Mendelman, MD as interim Chief Medical Officer.

• Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

  9/30/2019

  Aridis Pharmaceuticals, Inc. announced that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV and the Serum Institute of India, Ltd.

• Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

  9/27/2019

  Aridis Pharmaceuticals, Inc. announced it will present two posters at the Infectious Disease Society of America's IDWeek™ 2019, taking place October 2-6 in Washington, DC.

• Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

  9/27/2019

  Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 11:15 am ET.

• Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

  9/8/2019

  Aridis Pharmaceuticals, Inc. announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference.

• Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa

  9/3/2019

  Aridis Pharmaceuticals, Inc. announced results from the Company's first-in-patient Phase 2 clinical trial evaluating AR-105, a fully human IgG1 monoclonal antibody for the treatment of ventilator-associated pneumonia caused by gram-negative Pseudomonas aeruginosa (P. aeruginosa)

• Aridis Pharmaceuticals Announces Second Quarter 2019 Results

  8/12/2019

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the second quarter ended June 30, 2019.

• Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology

  7/30/2019

  Aridis Pharmaceuticals, Inc. announced that it has entered into an option agreement with the Serum International BV, an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units.

• Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501

  7/19/2019

  Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.

• Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501

  6/27/2019

  Aridis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.

• Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors

  6/10/2019

  Aridis Pharmaceuticals, Inc. announced the appointment of Susan Windham-Bannister, Ph.D., to its Board of Directors.

• Aridis Pharmaceuticals Announces First Quarter 2019 Results

  5/14/2019

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2019.

• Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update

  3/28/2019

  The Company, which is utilizing its proprietary MabIgX® antibody discovery platform to develop novel therapies for hospital acquired infections made considerable clinical development advances with its lead monoclonal antibody programs, AR-301 and AR-105, along with its cystic fibrosis (CF) candidate AR-501, an inhalable therapy to treat chronic lung infections impacting CF patients.

• AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients

  12/12/2018

  Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer

• Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

  12/4/2018

  CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million

• Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview

  11/13/2018

  Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market

• Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"

  11/7/2018

  Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine

• 

  Aridis Pharma Deepens Patents for Infectious Disease Therapies

  9/24/2018

  Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.

• Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates

  9/24/2018

  New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio

• Aridis Pharmaceuticals Announces Pricing of Initial Public Offering

  8/14/2018

  Aridis Pharmaceuticals, Inc. announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million